Nanhua iCell

Hunan Nanhua iCell Biotechnology Co., Ltd. (hereinafter referred to as the Company) is a controlled subsidiary of Nanhua Biomedicine Co., Ltd. Nanhua Biomedicine Co., Ltd. is a Shenzhen A-share main board listed company (stock code: SZ000504) with the People's Government of Hunan Province as the actual controller and Hunan Caixin Financial Holding Group as the controlling shareholder, with a registered capital of 31.157 million yuan. It is currently a domestic main board listed company in the stem cell, immune cell and tissue engineering industry controlled by state-owned capital. The Company has laboratories built according to EU GMP standards and related technical personnel, possesses strong scientific research and technical strength in the fields of stem cells and tissue engineering, and has rich experience in the production and preparation, storage, health anti-aging and clinical treatment of stem cells and immune cells. The Company's business scope covers biological resources, stem cell and immune cell storage and biotransformation medical technology services; biotechnology promotion services; medical information and technology consulting services; medical research and experimental development; medical testing technology development; medical testing technology services; research and development of biological products and drugs; sales of chemical reagents and auxiliaries (excluding monitored chemicals and dangerous chemicals), biological products, medical laboratory equipment and instruments, scientific testing instruments, medical teaching instruments, medical teaching models, cosmetics and sanitary products, and health products. Its core business is the construction and operation of the Nanhua Stem Cell Bank, as well as the production and preparation, storage, health anti-aging and clinical treatment of immune cells and other services.